The University of Louisville
Welcome,         Profile    Billing    Logout  
 8 Trials 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dryden, Gerald W
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT05437029: Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

Recruiting
1b
24
US
Q-Griffithsin 3.0, Q-Griffithsin Group 1, Q-Griffithsin 6.0, Q-Griffithsin Group 2
Kenneth Palmer, United States Department of Defense
COVID-19 Prevention
10/22
11/22
NCT01294072: Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue

Recruiting
N/A
35
US
curcumin, Curcumin conjugated with plant exosomes, No intervention
University of Louisville
Colon Cancer
11/24
11/24
MAAIS, NCT01169194: Multi-Center African-American Inflammatory Bowel Disease Study

Recruiting
N/A
2400
US
Johns Hopkins University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Disease
08/27
08/27
HBOT-UC, NCT05987852: Hyperbaric Oxygen Therapy for Ulcerative Colitis

Recruiting
N/A
126
US
Hyperbaric Oxygen Therapy, Sham Hyperbaric Air
Northwestern University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Ulcerative Colitis
09/27
09/27
Mann, Suzanne
No trials found

Download Options